Holen Sie sich die Stockscreener-App
0.4656
4.00%
-0.0194
Handel nachbörslich:
.48
0.0144
+3.09%
Schlusskurs vom Vortag:
$0.485
Offen:
$0.47
24-Stunden-Volumen:
456.07K
Relative Volume:
1.10
Marktkapitalisierung:
$25.25M
Einnahmen:
$3.10M
Nettoeinkommen (Verlust:
$-97.43M
KGV:
-0.2587
EPS:
-1.8
Netto-Cashflow:
$-94.38M
1W Leistung:
-2.31%
1M Leistung:
-42.05%
6M Leistung:
-74.83%
1J Leistung:
-87.31%
1-Tages-Spanne:
$0.455
$0.51
1-Wochen-Bereich:
$0.4431
$0.67
52-Wochen-Spanne:
$0.4431
$4.4599
Omega Therapeutics Inc Stock (OMGA) Company Profile
Firmenname
Omega Therapeutics Inc
Sektor
Branche
Telefon
(617) 949-4360
Adresse
140 FIRST STREET, SUITE 501, CAMBRIDGE
Vergleichen Sie OMGA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMGA
Omega Therapeutics Inc
|
0.4656 | 25.25M | 3.10M | -97.43M | -94.38M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-06-18 | Eingeleitet | Raymond James | Outperform |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-09-23 | Eingeleitet | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Aktie (OMGA) Neueste Nachrichten
Omega Therapeutics announces board reshuffle and new director - MSN
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Financial Times
Omega Therapeutics stock hits 52-week low at $0.52 - MSN
Omega Therapeutics stock hits 52-week low at $0.52 By Investing.com - Investing.com Canada
Omega Therapeutics faces loan default notice - Investing.com
Omega Therapeutics faces loan default notice By Investing.com - Investing.com UK
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Omega Therapeutics Announces Director Resignation - Investing.com
Omega Therapeutics Chair Resigns from Board of Directors - Defense World
Omega Therapeutics stock hits 52-week low at $0.74 - Investing.com India
Omega Therapeutics, Inc. Announces Resignation of Michelle C. Werner as Member of the Board of Directors and the Nominating and Corporate Governance Committee - Marketscreener.com
Omega Therapeutics Faces Leadership Change and Takeover Proposal - Yahoo Finance
Omega Therapeutics stock hits 52-week low at $0.74 By Investing.com - Investing.com Canada
Omega Therapeutics Inc (NASDAQ: OMGA) Down -65.47% This Year: What Is Going To Happen Next - Stocks Register
Omega Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Omega Therapeutics announces board changes By Investing.com - Investing.com Nigeria
Omega Therapeutics announces board changes - Investing.com India
Omega Therapeutics Appoints New Director Ravi Mehrotra - TipRanks
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - Citeline News & Insights
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates - MSN
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer – Company Announcement - Financial Times
Piper Sandler Lowers Omega Therapeutics (NASDAQ:OMGA) Price Target to $4.00 - Defense World
Omega Therapeutics Reports Third Quarter 2024 Results - TipRanks
Omega Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Omega Therapeutics stock target cut, keeps Overweight on clinical updates By Investing.com - Investing.com Canada
Shares of Flagship-founded biotech fall as CEO departs - The Business Journals
Omega Therapeutics (NASDAQ:OMGA) Downgraded to Market Perform Rating by Raymond James - MarketBeat
Piper Sandler Issues Pessimistic Forecast for Omega Therapeutics (NASDAQ:OMGA) Stock Price - MarketBeat
Omega Therapeutics Inc (OMGA) Quarterly 10-Q Report - Quartzy
Omega Therapeutics Names Kaan Certel as CEO - MarketWatch
Omega Therapeutics Announces Successful Completion of Phase - GlobeNewswire
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results - The Manila Times
Omega Therapeutics, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner - Financial Times
Omega Therapeutics (NASDAQ:OMGA) Stock Price Down 0.9%Should You Sell? - MarketBeat
Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight - GlobeNewswire
Finanzdaten der Omega Therapeutics Inc-Aktie (OMGA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):